Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2016 - 2017)

Historic Cash from Discontinued Operations for Protalix BioTherapeutics (PLX) over the last 3 years, with Q3 2017 value amounting to $2000.0.

  • Protalix BioTherapeutics' Cash from Discontinued Operations rose 10067.57% to $2000.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $116000.0, marking a year-over-year decrease of 9718.92%. This contributed to the annual value of -$11000.0 for FY2016, which is 10074.02% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Cash from Discontinued Operations stood at $2000.0 for Q3 2017, which was up 10067.57% from -$8000.0 recorded in Q2 2017.
  • Over the past 5 years, Protalix BioTherapeutics' Cash from Discontinued Operations peaked at $4.1 million during Q4 2015, and registered a low of -$1.4 million during Q3 2015.
  • For the 3-year period, Protalix BioTherapeutics' Cash from Discontinued Operations averaged around $159100.0, with its median value being -$131000.0 (2015).
  • As far as peak fluctuations go, Protalix BioTherapeutics' Cash from Discontinued Operations skyrocketed by 16471.77% in 2016, and later crashed by 10124.61% in 2017.
  • Quarter analysis of 3 years shows Protalix BioTherapeutics' Cash from Discontinued Operations stood at $4.1 million in 2015, then crashed by 107.15% to -$296000.0 in 2016, then skyrocketed by 100.68% to $2000.0 in 2017.
  • Its Cash from Discontinued Operations stands at $2000.0 for Q3 2017, versus -$8000.0 for Q2 2017 and $122000.0 for Q1 2017.